Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Overactive bladder Stories

2011-05-16 08:00:00

WASHINGTON, May 16, 2011 /PRNewswire/ -- An estimated one in three women experience stress urinary incontinence (SUI), a condition characterized by involuntary loss of urine due to forces on the bladder caused by physical movement of the body. Although SUI can interfere with quality of life, it is often left untreated due to the personal nature of its symptoms which leave women feeling embarrassed about their bodies and hesitant to discuss or report their urinary leakage. To bridge this...

2011-05-16 06:00:00

MINNEAPOLIS, May 16, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the fourth quarter and full fiscal year ended March 31, 2011, at the market close on Wednesday, May 25, 2011. The Company will host a conference call to discuss these results on Wednesday, May 25, 2011 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial...

2011-04-25 05:55:00

MINNETONKA, Minn., April 25, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of clinical studies using Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products are scheduled to be presented at three upcoming professional meetings. The meetings include...

2011-04-08 07:00:00

MINNETONKA, Minn., April 8, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI) announced that NHIC Corp., the Medicare carrier for Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island and Vermont, will cover posterior tibial nerve stimulation (PTNS) using Uroplasty's Urgent® PC Neuromodulation System for the treatment of overactive bladder and associated symptoms, effective May 22, 2011. This decision adds approximately 1.8 million lives to those already covered...

2011-04-05 06:30:00

MINNEAPOLIS, April 5, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that two private insurance payers have elected to cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder (OAB) and associated symptoms. Effective April 1, 2011, UnitedHealthcare, a nationwide...

2011-04-04 23:26:47

Much of the risk of developing incontinence before middle age is determined by our genes. Genetic factors can explain half of people's susceptibility to urinary incontinence, a study of twins at the University of Gothenburg and Karolinska Institutet (Sweden) reveals. Urinary incontinence is very common, especially among women, with around one in three affected at some point in life. Incontinence, overactive bladder and other lower urinary tract symptoms can be caused by factors such as old...

2011-03-22 09:36:00

TOKYO, March 22, 2011 /PRNewswire-FirstCall/ -- Astellas Pharma Inc.(TSE:4503,"Astellas") ( http://www.astellas.com/en/corporate/) today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition[1,2]. These data were presented for the first time this week at...

2011-03-02 00:00:26

Michelle Persun, MD, has joined Urologic Consultants of Southeastern Pennsylvania. She has a special interest in treating incontinence in women and men and in treating female urologic problems. She is spearheading a new specialty center for incontinence and pelvic disorders at One Presidential Boulevard in Bala Cynwyd, Pa. The center offers a multidisciplinary, holistic approach to treating stress incontinence, overactive bladder, pelvic organ prolapse, pelvic pain, urinary tract infections...

2011-01-20 06:00:00

MINNEAPOLIS, Jan. 20, 2011 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI) announced today that it will release financial results for the third quarter ended December 31, 2010, at the market close on Thursday, January 27, 2011. The Company will host a conference call to discuss these results on Thursday, January 27, 2011 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial Officer and...

2011-01-11 09:08:00

WAYNE, Pa., Jan. 11, 2011 /PRNewswire/ -- FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder (OAB). The Phase II FP 1097 trial demonstrated that drug can be delivered to the bladder via intra-vaginal administration successfully. The clinical trial showed a...